LITOSeek by Novigenix is an AI-powered immune liquid biopsy platform that uses immuno-transcriptomics to transform precision oncology. By measuring the gene activity of millions of immune cells in blood and integrating this data with tumor DNA, other omics, and clinical metadata, LITOSeek delivers highly precise, predictive insights across the cancer patient journey. The platform enables early cancer detection, robust immune biomarker discovery, therapy response prediction, toxicity biomarker identification, and deep understanding of mechanisms of response and resistance. ISO13485 certification underpins its use in clinical development and precision medicine, helping pharmaceutical and biotech partners accelerate development of effective therapies and improve patient outcomes.